Get the Stockscreener App
2.48
5.98%
0.14
After Hours:
2.48
Ocugen Inc stock is traded at $2.48, with a volume of 15.40M.
It is up +5.98% in the last 24 hours and up +75.89% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$2.34
Open:
$2.46
24h Volume:
15.40M
Relative Volume:
2.51
Market Cap:
$813.19M
Revenue:
$4.41M
Net Income/Loss:
$-67.85M
P/E Ratio:
-10.98
EPS:
-0.2258
Net Cash Flow:
$-57.15M
1W Performance:
+54.04%
1M Performance:
+75.89%
6M Performance:
+131.78%
1Y Performance:
+357.14%
1-Day Range:
$2.405
$2.67
1-Week Range:
$1.54
$2.67
52-Week Range:
$0.515
$2.67
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
2.48 | 813.19M | 4.41M | -67.85M | -57.15M | -0.2258 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-26 | Initiated | Oppenheimer | Outperform |
| Oct-15-24 | Initiated | Maxim Group | Buy |
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Ocugen (OCGN) Is Up 54.0% After Completing Phase 3 OCU400 Enrollment And Facing Going-Concern Warning - simplywall.st
Why Ocugen (OCGN) Is Up 54.0% After OCU400 Phase 3 Progress And Going Concern Spotlight - Yahoo Finance
Analyst Confidence Sparks Surge in Ocugen Shares - AD HOC NEWS
Ocugen Stock Jumps as Oppenheimer Initiates Outperform Rating - StocksToTrade
Ocugen’s Shares Leap 32% Post Oppenheimer’s Positive Coverage - timothysykes.com
Ocugen Stock Surges Amid Positive Analyst Coverage and Clinical Progress - StocksToTrade
Ocugen Stock Surges Amid Oppenheimer’s Bullish Forecast - timothysykes.com
Ocugen, Inc. (NASDAQ: OCGN) Q4 2025 earnings call transcript - MSN
Ocugen Stock Soars Following Strategic Developments in Gene Therapy Trials - timothysykes.com
Oppenheimer Starts Ocugen (OCGN) at Outperform on Gene Therapy Pipeline - AOL.com
Ocugen (OCGN) Q4 2025 Earnings Call Transcript - AOL.com
How Ocugen (OCGN) Phase 2 And Phase 3 Milestones Are Reframing The Investment Story - Yahoo Finance
Ocugen (OCGN) Valuation Update As Phase 3 OCU400 Enrollment Completes And Going Concern Risks Persist - simplywall.st
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the Making - AOL.com
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction - AOL.com
Ocugen (OCGN) Surges to 52-Week High on Oppenheimer's Outperform Rating - GuruFocus
Investors Buy Large Volume of Ocugen Call Options (NASDAQ:OCGN) - MarketBeat
Ocugen stock wins new Outperform at Oppenheimer (OCGN:NASDAQ) - Seeking Alpha
Ocugen (NASDAQ:OCGN) Hits New 12-Month HighWhat's Next? - MarketBeat
OCGN: Oppenheimer Initiates Coverage with Outperform Rating | OC - GuruFocus
HC Wainwright Brokers Increase Earnings Estimates for Ocugen - MarketBeat
Oppenheimer Initiates Ocugen at Outperform With $10 Price Target - marketscreener.com
Oppenheimer initiates Ocugen stock rating at Outperform on gene therapy potential - Investing.com
Ocugen price target raised to $22 from $15 at Lucid Capital - TipRanks
Oppenheimer initiates coverage of Ocugen (OCGN) with outperform recommendation - MSN
Ocugen's Clinical Ambition Meets Market Skepticism - AD HOC NEWS
Ocugen’s Gene Therapy Pipeline Dominates Earnings Call - TipRanks
Ocugen Faces Analyst Scrutiny Despite Pipeline Progress - AD HOC NEWS
Ocugen Reports 2025 Results and Clinical Progress Across Gene Therapy Pipeline - MyChesCo
Is ArriVent BioPharma, Inc. (AVBP) Stock Outpacing Its Medical Peers This Year? - Yahoo! Finance Canada
FY2030 Earnings Forecast for Ocugen Issued By HC Wainwright - MarketBeat
Ocugen Completes Enrollment for Phase 3 Trial of OCU400 Gene Therapy - MyChesCo
Ocugen: Downgrade "Hold" After OCU410 Data Release (NASDAQ:OCGN) - Seeking Alpha
312,319,623 Common Stock of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Certain Warrants of Ocugen, Inc. are subject to a Lock-Up Agreement Ending on 9-MAR-2026. - marketscreener.com
Ocugen, Inc. honors women leaders advancing gene therapy innovation - Traders Union
Is Ocugen Inc. (2H51) stock worth buying before Fed actionInsider Selling & Free High Return Stock Watch Alerts - Naître et grandir
Will Ocugen Inc. stock continue upward momentumTrade Exit Report & AI Optimized Trade Strategies - Naître et grandir
Ocugen’s Growing Pains: High Execution and Compliance Risks Threaten Shareholder Value - The Globe and Mail
Ocugen (NASDAQ:OCGN) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Employee dedication drives gene therapy progress, Ocugen, Inc. asserts - Traders Union
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen (NASDAQ:OCGN) Trading Down 7.2%Here's Why - MarketBeat
OCGN Analyst Rating Maintained by Chardan Capital at Buy with $7 - GuruFocus
Ocugen (NASDAQ:OCGN) Receives "Buy" Rating from Chardan Capital - MarketBeat
Ocugen, Inc. Hits New 52-Week High of $2.00, Marking Major Milestone - Markets Mojo
Ocugen, Inc. (NASDAQ:OCGN) Q4 2025 Earnings Call Transcript - Insider Monkey
Ocugen Posts Wider FY25 Loss, Advances Gene Therapy And Vaccine Pipeline - Nasdaq
Ocugen Q4 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Ocugen Q4 2025 reveals steady R&D investment By Investing.com - Investing.com South Africa
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.48%
1.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):